제2형 당뇨병 시장(2026-2030년)

The global type 2 diabetes market is forecasted to grow by USD 59896.1 mn during 2025-2030, accelerating at a CAGR of 12.2% during the forecast period. The report on the global type 2 diabetes market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by integration of advanced medical devices and automated glycemic control, expansion of pharmacological indications to address cardiovascular and renal comorbidities, increasing prevalence of diabetes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global type 2 diabetes market is segmented as below:

By Drug Class

• Insulin
• DPP-4 inhibitor
• GLP-1 receptor agonists
• SGLT-2 inhibitors
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Delivery Mode

• Oral
• Injectable
• Continuous glucose monitoring (CGM)

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integration of AI and predictive analytics in chronic management as one of the prime reasons driving the global type 2 diabetes market growth during the next few years. Also, advancement of long-acting and non-invasive therapeutic formulations and decentralization of care through digital pharmacy and temperature-controlled logistics will lead to sizable demand in the market.

The report on the global type 2 diabetes market covers the following areas:

• Global type 2 diabetes market sizing
• Global type 2 diabetes market forecast
• Global type 2 diabetes market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global type 2 diabetes market vendors that include Abbott Laboratories, AstraZeneca Plc, Bayer AG, Biocon Ltd., Boehringer Ingelheim GmbH, Dexcom Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Insulet Corp., Lupin Ltd., Medtronic Plc, Merck and Co. Inc., MicroPort Scientific Corp., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries, Takeda Pharmaceutical Ltd., Tandem Diabetes Care Inc., Terumo Corp.. Also, the global type 2 diabetes market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Delivery Mode
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Type 2 Diabetes Market 2020 - 2024
  • Historic Market Size - Data Table on Global Type 2 Diabetes Market 2020 - 2024 ($ million)
• 5.2 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Delivery Mode segment analysis 2020 - 2024
  • Historic Market Size - Delivery Mode Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Type 2 Diabetes Market
• 6.2 Impact of geopolitical conflict on Global Type 2 Diabetes Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Drug Class

• 8.1 Market segments
• 8.2 Comparison by Drug Class
• 8.3 Insulin - Market size and forecast 2025-2030
• 8.4 DPP-4 inhibitor - Market size and forecast 2025-2030
• 8.5 GLP-1 receptor agonists - Market size and forecast 2025-2030
• 8.6 SGLT-2 inhibitors - Market size and forecast 2025-2030
• 8.7 Others - Market size and forecast 2025-2030
• 8.8 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Retail pharmacies - Market size and forecast 2025-2030
• 9.4 Hospital pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Delivery Mode

• 10.1 Market segments
• 10.2 Comparison by Delivery Mode
• 10.3 Oral - Market size and forecast 2025-2030
• 10.4 Injectable - Market size and forecast 2025-2030
• 10.5 Continuous glucose monitoring (CGM) - Market size and forecast 2025-2030
• 10.6 Market opportunity by Delivery Mode
  • Market opportunity by Delivery Mode ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 France - Market size and forecast 2025-2030
  • 12.4.3 UK - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Turkey - Market size and forecast 2025-2030
  • 12.5.6 Indonesia - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 South Africa - Market size and forecast 2025-2030
  • 12.6.4 Israel - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 Egypt - Market size and forecast 2025-2030
  • 12.6.7 UAE - Market size and forecast 2025-2030
  • 12.6.8 Colombia - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Integration of advanced medical devices and automated glycemic control
  • Expansion of pharmacological indications to address cardiovascular and renal comorbidities
  • Increasing prevalence of diabetes
• 13.2 Market challenges
  • Escalating economic burden and reimbursement hurdles
  • Therapeutic inertia and complexity of long-term patient adherence
  • Manufacturing constraints and global supply chain disruptions
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Integration of AI and predictive analytics in chronic management
  • Advancement of long-acting and non-invasive therapeutic formulations
  • Decentralization of care through digital pharmacy and temperature-controlled logistics

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.5 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Business segments
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Segment focus
  • SWOT
• 15.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.7 Biocon Ltd.
  • Biocon Ltd. - Overview
  • Biocon Ltd. - Business segments
  • Biocon Ltd. - Key offerings
  • Biocon Ltd. - Segment focus
  • SWOT
• 15.8 Dexcom Inc.
  • Dexcom Inc. - Overview
  • Dexcom Inc. - Product / Service
  • Dexcom Inc. - Key offerings
  • SWOT
• 15.9 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 15.10 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 15.12 Medtronic Plc
  • Medtronic Plc - Overview
  • Medtronic Plc - Business segments
  • Medtronic Plc - Key news
  • Medtronic Plc - Key offerings
  • Medtronic Plc - Segment focus
  • SWOT
• 15.13 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.16 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 15.17 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 15.18 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations